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ABSTRACT
Osteosarcoma (OS) is the most common malignant bone tumor in children and 
adolescents. The present study investigated the expression of Cytochrome P-450 
(CYP) genes: CYP1A2, CYP3A4 and CYP3A5 by qRT-PCR in 135 specimens obtained 
from OS patients, including biopsy (pre-chemotherapy), tumor resected in surgery 
(post-chemotherapy), adjacent bone to tumor (nonmalignant tissue), pulmonary 
metastasis and adjacent lung to metastasis (nonmalignant tissue). Normal bone and 
normal lung tissues were used as control. We also investigated in five OS cell lines the 
modulation of CYPs expression by cisplatin, doxorubicin and methotrexate. As result, 
the adjacent lung specimens presented CYP1A2 overexpression compared to the 
normal lung (p=0.0256). Biopsy specimens presented lower CYP3A4 expression than 
normal bone (p=0.0314). The overexpression of both CYP1A2 and CYP3A4 in post-
chemotherapy specimens were correlated with better event free-survival (p=0.0244) 
and good response (p=0.0484), respectively. Furthermore, in vitro assays revealed 
that CYP1A2 was upregulated by doxorubicin (p=0.0034); CYP3A4 was upregulated 
by cisplatin, doxorubicin and methotrexate (p=0.0004, p=0.0024, p<0.0001, 
respectively); and CYP3A5 was downregulated by doxorubicin (p=0.0285) and 
upregulated in time-dependent manner by methotrexate (p=0.0239). In conclusion, 
our findings suggest that CYP genes play an important role in OS tumorigenesis, at 
primary and metastatic sites, as well in treatment response.
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INTRODUCTION
Osteosarcoma (OS) originates from primitive 
mesenchymal cells and it is the most common malignant 
bone tumor in children and adolescents [1]. OS treatment 
still uses the same drugs since 1980s and survival rates have 
not been improved since then, consequently translational 
research is required to identify targets for novel treatment 
modalities [2]. Cytochrome P-450 (CYP) enzymes 
participate in the phase I of drug metabolism, mediating 
drug oxidation, reduction and hydrolysis reactions, therefore 
activating or deactivating drugs during these processes [3, 
4]. The CYP enzymes also mediate metabolic activation 
of procarcinogens, thus they could play a role in both 
tumorigenesis and treatment response [4].
Although many CYP members detoxify anticancer 
drugs used in OS treatment, such as ifosfamide, 
doxorubicin, etoposide and cisplatin [5, 6], the impact of 
CYP to treatment response and prognosis in OS needs to 
be further explored and defined [5]. Dhaini et al. found a 
higher frequency of CYP1A2 expression detection in OS 
biopsy fragments than in most cancers investigated (80%) 
[7]. CYP1A2 gene expression has already been detected in 
human lung tissue [8], the main metastatic site in OS. In 
OS patients, the variant rs4646437 in CYP3A4 gene has 
been associated with 5-year progression-free survival [9]. 
Mensah-Osman et al. verified that Pregnane Xenobiotic 
Receptor (PXR) plays a critical role in CYP3A4 gene 
expression regulation in OS and its activation may influence 
the chemotherapy effect in target genes implicating drug 
resistance [10]. In addition, analyses of CYP3A4/5 
expression in OS biopsies revealed that high expression 
might predict metastasis and poor prognosis in OS [7].
The CYP enzymes are involved in the biosynthesis 
or catabolism of steroid hormones, bile acids, fat-soluble 
vitamins, fatty acids, and eicosanoids, which play a role 
in important pathways [11]. The CYP1A2 enzyme can 
convert several procarcinogens, including polycyclic 
aromatic hydrocarbons (PAHs), heterocyclic amines, and 
aflatoxin B1 (AFB1) to reactive electrophiles that can 
interact with DNA and proteins [12]. Thus, differences in 
CYP1A2 activity may influence individual susceptibility to 
cancer risk [4]. Polymorphisms in the CYP1A2 gene have 
already been related with cancer risk in liver, lung, stomach, 
pancreas, breast, endometrium and ovarian [13–19]. As for 
drugs, CYP3A enzyme also plays an important role in the 
metabolism of several endogenous substances, including 
testosterone and progesterone [20]. Polymorphism in 
CYP3A4 gene was associated with early puberty [21] and 
has been associated with a high grade and advanced stage of 
prostate cancers [22]. Furthermore, a meta-analysis showed 
that polymorphism in CYP3A5 gene may increase the cancer 
risk, especially in acute leukemia, chronic leukemia, and 
colorectal cancer [23]. The major sources of variability 
in CYP activities are environmental influences, including 
inhibition or induction by drugs; biological factors including 
sex and physiological determinants, such as hormonal status, 
disease, and circadian rhythms; and genetic polymorphisms 
in both CYP genes and their regulators [20].
Therefore, the aim of the present study was to 
investigate if the expression levels of CYP1A2, CYP3A4 and 
CYP3A5 genes play a role in OS tumorigenesis and treatment 
response. Thus, we analyzed different specimens in time for 
each OS patient during the treatment and disease progression. 
As well, we investigated nonmalignant tissues surrounding 
the tumor, such as bone and lung tissues that could play 
an important role in priming the microenvironment for OS 
establishment. This study also investigated if the major drugs 
used in OS treatment and their different combinations could 
modulate CYP genes expression in OS cell lines.
RESULTS
Gene expression of CYP1A2, CYP3A4 and 
CYP3A5 in OS patients and controls
CYP1A2 gene expression and its association with 
pulmonary microenvironment in OS metastasis could be 
observed in Figure 1. The adjacent lung to pulmonary OS 
metastasis specimens presented CYP1A2 overexpression 
compared to normal lung (p=0.0256), adjacent bone 
(p<0.0001) and normal bone (p=0.0015) specimens 
(Figure 1A). The CYP1A2 gene overexpression observed 
in adjacent lung to OS metastasis specimens was exclusive 
for this CYP gene among the others investigated, as 
CYP3A4 (p<0.0001) and CYP3A5 (p=0.0168).
It was also observed a difference in CYP3A4 and 
CYP3A5 gene expression in analyzed specimens (Figure 2A 
and 2B, respectively). Biopsy specimens presented lower 
CYP3A4 expression than normal bone specimens (p=0.0314). 
Surgery specimens presented CYP3A4 overexpression than 
biopsy (p<0.0001) and first occurred metastasis specimens 
from each patient (p=0.0006). In CYP3A5 gene expression 
analyses, surgery specimens presented higher expression 
than biopsy specimens (p=0.0157) and lower expression than 
metastasis at diagnosis specimens (p=0.0066).
Furthermore, CYPs gene expression showed to be 
associated with the outcome of OS patients (Figure 3). The 
survival curves of OS patients were analyzed according 
high expression (more or equal than median value) and 
low expression (less than median value) of CYP genes. In 
this analysis, we have separated two independent groups 
of patients: metastatic and nonmetastatic at diagnosis, 
since metastasis at diagnosis is an important prognostic 
factor in OS. When only nonmetastatic patients at 
diagnosis were analyzed, the CYP1A2 overexpression in 
surgery specimens was associated with a better event-
free survival (p=0.0244) (Figure 3A). Also, CYP3A4 
overexpression in adjacent bone specimens was associated 
with good response (tumor necrosis grade higher than 90% 
- grades III and IV) (p=0.0484) and conservative surgery 
(p=0.0329) (Figure 3B and 3C, respectively).
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Gene expression of CYP1A2, CYP3A4 and 
CYP3A5 in OS cell lines untreated and treated 
with chemotherapeutic drugs
Although all OS cell lines have been treated with 
IC50, some samples did not show a good quality of RNA, 
probably due to drugs effects, thus they were excluded 
from analyses. The present investigation showed 
that the M-OS cell line untreated presented CYP1A2 
overexpression than other OS cell lines (p=0.0464) 
(Figure 1C). Analyses of CYP genes expression in OS 
cell lines untreated (control) and treated with cisplatin, 
doxorubicin, methotrexate, cisplatin plus doxorubicin 
(CD), cisplatin plus doxorubicin plus methotrexate (CDM) 
were showed in Figure 4. The doxorubicin, CD and CDM 
treatments upregulated the CYP1A2 expression in OS cell 
lines (p=0.0034, p=0.0068 and p=0.0020, respectively) 
(Figure 4A). All the five treatments (cisplatin, 
doxorubicin, methotrexate, CD and CDM) upregulated 
the CYP3A4 expression in OS cell lines (p=0.0004, p= 
0.0024, p<0.0001, p=0.0472 and p=0.0362, respectively) 
(Figure 4B). The CYP3A5 expression in OS cell lines was 
downregulated after treatments with doxorubicin, CD and 
CDM (p=0.0285, p=0.0463 and p=0.0108, respectively) 
(Figure 4C). Additionally, treatment with methotrexate 
showed an increased expression of CYP3A4 and CYP3A5 
genes in a time-dependent manner (p=0.0085 and 
p=0.0239, respectively) (Figure 4B and 4C), in which 72 
hours of treatment resulted in higher gene expression than 
24 hours of treatment.
DISCUSSION
The CYP enzymes are involved in the biosynthesis 
or catabolism of several endogenous compounds involved 
in a variety of important pathways [11]. Furthermore, 
Figure 1: CYP1A2 expression and its correlation with OS metastasis and metastatic tumor microenvironment. A. 
Kruskal-Wallis Test (p<0.0001). Analyses between two groups were done by Mann-Whitney Test that confirmed CYP1A2 overexpression 
in adjacent lung to OS metastasis in comparison with normal bone (control of the bone tissue) (p=0.0015), adjacent bone to primary OS 
(p<0.0001) and normal lung (control of the lung tissue) (p=0.0256). B. Friedman Test (p<0.0001). Dunn’s multiple comparisons test 
confirmed CYP1A2 overexpression in comparison with CYP3A4 (p<0.0001) and CYP3A5 (p=0.0168) in adjacent lung to OS metastasis. 
C. Kruskal-Wallis Test. CYP1A2 overexpression in M-OS cell line, established from OS metastasis in the lung (p=0.0464). Statistical 
significance: *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.
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Figure 2: CYP3A4 and CYP3A5 genes expression in OS specimens and normal bone. A. CYP3A4 gene expression. Biopsy 
presented lower expression than normal bone specimens. Surgery specimens presented higher expression than biopsy. First metastasis from 
each patient presented lower expression than surgery and normal bone specimens, presenting similar expression to biopsy. B. CYP3A5 
gene expression. Surgery specimens presented overexpression than biopsy and lower expression than metastasis at diagnosis specimens. 
Statistical significance by Mann-Whitney and Wilcoxon Test: *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.
Figure 3: CYPs gene expression and outcome in OS. A. Event-free survival of nonmetastatic at diagnosis patients according to 
high expression (more or equal than median value) and low expression (less than median value) of CYP1A2 gene. The median value of 
CYP1A2 relative quantification was 0.3797 in surgery specimens. B. Mann-Whitney Test. CYP3A4 expression in adjacent bone specimens 
(post-chemotherapy), according tumor necrosis grade. C. Mann-Whitney Test. CYP3A4 expression in adjacent bone specimens (post-
chemotherapy), according to type of surgery.
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Figure 4: CYPs gene expression in OS cell lines treated with cisplatin, doxorubicin, methotrexate, cisplatin plus 
doxorubicin (CD), and cisplatin plus doxorubicin plus methotrexate (CDM). A. CYP1A2 upregulation by doxorubicin, CD 
and CDM treatments. B. CYP3A4 upregulation by cisplatin, doxorubicin, methotrexate, CD and CDM treatments, whereas upregulation 
by methotrexate was time-dependent. C. CYP3A5 downregulation by doxorubicin, CD and CDM treatments, whereas methotrexate 
upregulated in a time-dependent manner. Statistical significance by Mann-Whitney and Wilcoxon: *: p<0.05; **: p<0.01; ***: p<0.001; 
****: p<0.0001.
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CYP members can detoxify anticancer drugs used in OS 
treatment, such as doxorubicin and cisplatin [5]. Thus, 
CYP members could play a role in both tumorigenesis and 
treatment response [4]. To the best of our knowledge, this 
is the first study that investigated CYP gene expression 
in primary and metastatic OS, as well as in nonmalignant 
tissue surrounding the tumor, in order to investigate 
CYP role in priming tumor microenvironment and 
tumorigenesis in OS. Also, for the first time CYP gene 
expression was correlated with the outcome in OS and the 
modulation of its expression was investigated in vitro by 
the main chemotherapeutic drugs used in OS treatment.
The present study revealed that adjacent lung 
specimens presented CYP1A2 overexpression, but not 
CYP3A4 and CYP3A5, when compared to normal lung 
specimens. It was also observed that biopsy specimens 
presented lower CYP3A4 gene expression than normal 
bone specimens. Surgery specimens, representing post-
chemotherapy tumors, showed both CYP3A4 and CYP3A5 
overexpression. Metastasis specimens presented lower 
CYP3A4 expression, but higher CYP3A5 expression, 
than surgery specimens. The current analysis showed 
that surgery specimens with CYP1A2 overexpression 
are associated with a better event-free survival in 
nonmetastatic patients at diagnosis. Furthermore, adjacent 
bone specimens showed CYP3A4 gene overexpression in 
patients that presented good response or were submitted to 
conservative surgery. In vitro assays showed that CYP1A2 
expression was upregulated by doxorubicin; CYP3A4 
expression was upregulated by cisplatin, doxorubicin and 
methotrexate; and CYP3A5 expression was downregulated 
by doxorubicin and upregulated in a time-dependent 
manner by methotrexate.
The CYP1A2 overexpression exclusively in the 
adjacent lung tissue showed that this CYP member 
might contribute to a favorable microenvironment in the 
lung during OS metastasis establishment. Interestingly, 
the M-OS cell line, established from pulmonary OS 
metastasis, also showed CYP1A2 overexpression, which 
emphasizes a possible correlation between CYP1A2 and 
pulmonary OS metastasis. Polymorphisms in the CYP1A2 
gene have already been correlated with cancer risk in 
liver, lung, stomach, pancreas, breast, endometrium and 
ovarian [13–19]. Several meta-analyses showed that 
the polymorphism 164A>C in CYP1A2 gene can result 
in 2–3 fold increase in the CYP1A2 activity, which has 
been associated with increased cancer risk, primarily lung 
cancer in Caucasians [24–27]. Interestingly, 82% of the 
adjacent lung specimens analyzed in the present study 
were obtained from Caucasians.
The CYP1A2 enzyme could contribute to an ideal 
microenvironment in the lung through several ways. First, 
benzo[a]pyrene, a CYP1 enzyme substrate and a PAH 
present in organic material combustion, such as, diesel and 
food, has implicated in the induction of cell proliferation 
as well as tumors including OS [28]. Moreover, CYP1 
metabolism of both xenobiotics and endobiotics leads 
to reactive oxygen species (ROS) formation, which can 
cause genotoxicity, and lead to inflammation, another 
source of ROS formation [29]. Furthermore, a regulatory 
feedback loop between AHR (aryl hydrocarbon receptor) 
and CYP1 genes is known, thus AhR interacts with 
nuclear factor κb (NFκB), estrogen receptor 1 (ESR1) and 
retinoblastoma 1 (RB1), which triggers the transcription 
of genes involved in growth, cell cycle and apoptosis, 
leading to abnormal growth and tumor promotion [29]. 
For example, the AHR/RB1 complex, could cause RB1 
hyperphosphorylation and cell cycle progression [30]. 
Also, it is already known a strong correlation between RB1 
mutations and OS tumorigenesis [31, 32], showing that 
AHR/CYP1 modulation could influence OS tumorigenesis 
and maintenance.
The low CYP3A4 expression in the biopsy suggested 
its role in OS tumorigenesis. The CYP3A4 enzyme has the 
highest abundance in the human liver (~40%) [33] and is 
involved in the oxidative deactivation of testosterone [34, 
35]. Testosterone plays a crucial role in bone metabolism 
and pubertal growth spurt [36], and it could be mediated 
by activation via Akt (serine/threonine kinase) and 
MAPK (mitogen-activated protein kinase) [37]. In this 
sense, MAPK7 has already been studied in OS and might 
be a promising therapeutic target for this tumor, since 
modulates growth, proliferation and migration in OS [38].
As we observed increase of the CYP3A4 expression 
in surgery specimens, we propose that it might have 
occurred due to chemotherapy treatment. However, 
metastasis specimens showed lower CYP3A4 expression 
than surgery and normal bone specimens, demonstrating 
a similar pattern observed in biopsy specimens. On the 
other hand, the upregulation of CYP3A5 expression 
not only occurred when surgery and biopsy specimens 
were compared, but also when metastasis specimens 
were compared with normal bone, biopsy and surgery 
specimens. Although the transcriptional regulation 
of CYP3A4 and CYP3A5 genes are done by the same 
receptor, PXR [39], the present study showed a similar 
CYP3A4 expression in biopsy and metastasis specimens, 
which could be related to some resistance mechanism.
Our findings as to CYP overexpression and good 
outcome in OS patients are in agreement with other CYP 
studies of drug toxicity [29]. The correlation between 
CYP1A2 overexpression and better event-free survival, 
probably is due to doxorubicin toxicity mediated by 
CYP1A2 enzyme against OS cancer cells, since CYP1A2 
metabolizes this chemotherapy drug [40]. The association 
between CYP3A4 overexpression and good response 
objected to what has been found by Dhaini et al., which 
showed that high CYP3A4/5 expression may predict 
metastasis and poor prognosis in OS [7]. The contrast 
could be explained by differences in analyzed samples. 
The present study showed an association with post-
chemotherapy specimens, while Dhaini et al. investigated 
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only pre-chemotherapy samples. Moreover, the present 
results regarding patients’ specimens and in vitro assays, 
demonstrated that chemotherapy upregulates CYP3A4, 
which enzyme participates in cisplatin and doxorubicin 
metabolism [5].
In vitro assays showed that treatments with 
doxorubicin, CD or CDM upregulated CYP1A2 
expression in OS cell lines. In H9c2 cell lines, derived 
from heart, there was already reported a significant 
induction of CYP1A2 expression by doxorubicin, as 
well as in breast cancer MCF7 cell line doxorubicin-
resistant [40, 41]. These findings could be explained by 
AhR protein induction by doxorubicin, once CYP1A2 
gene is coordinately regulated at the transcriptional level 
by AhR protein [42]. Regarding CYP3A4 expression, 
it was observed upregulation in OS cell lines by all five 
treatments. Moreover, cell lines treated with methotrexate 
showed CYP3A4 upregulation time-dependent, whereas 
the treatment for 72 hours presented higher expression 
than 24 hours. This regulation could be mediated by 
PXR, which is the major responsible for CYP3A4 gene 
transcription [10, 12] and has already known to be 
expressed in OS cell lines, such as HOS, MG-63, and 
Saos-2 [43].
Although the transcriptional regulation of CYP3A4 
and CYP3A5 genes are performed by the same receptor, 
PXR [39], our findings in vitro showed that CYP3A4 
and CYP3A5 genes were differently regulated by 
chemotherapy. Treatment with doxorubicin, CD and CDM 
in OS cell lines, different of CYP3A4, downregulated 
CYP3A5 expression. However, it was observed CYP3A5 
overexpression in post-chemotherapy OS specimens. We 
suggest that methotrexate upregulated CYP3A5 expression 
in patients’ specimens, due to in vitro assays have shown 
CYP3A5 overexpression in 72 hours of methotrexate 
treatment than in 24 hours. Therefore, a longer time 
of methotrexate treatment could increase even more 
CYP3A5 expression. Thus, CYP3A5 gene upregulation 
by methotrexate could prevail over downregulation 
by doxorubicin, since methotrexate is administrated in 
patients twice per cycle of chemotherapy and doxorubicin 
is administrated only once per cycle.
The CYP enzymes played controversial roles during 
time. In the pre-1968 era, CYP enzymes were thought 
to be beneficial because of detoxification, in the 1968–
1998 era everyone was convinced that CYP enzymes 
were always detrimental, and since 1998 it seems more 
protective than destructive during environmental injury 
[29]. So, these controversial opinions probably were due to 
its great importance in several metabolism and molecular 
pathways. Thus, the present study showed that CYPs gene 
expression could play a role in different ways, depending 
if their influence was considered in tumorigenesis or 
treatment response. Due to that, CYP genes should be 
more explored in OS, a complex disease, to clarify these 
correlations.
In conclusion, the present study showed that 
adjacent lung to OS metastasis presented CYP1A2 
overexpression, indicating its role in priming a favorable 
microenvironment during the establishment of OS lung 
metastasis. Moreover, biopsy specimens presented 
lower CYP3A4 expression than normal bone, which 
suggests a possible correlation between CYP3A4 and OS 
tumorigenesis. The CYP1A2 and CYP3A4 overexpression 
post-chemotherapy were correlated with a better event 
free-survival and a better treatment response, respectively, 
probably due to the role of CYP1A2 and CYP3A4 
enzymes in chemotherapy drugs metabolism. Additionally, 
in OS cell lines was verified that the own drugs used in OS 
treatment modulated CYPs gene expression. Therefore, the 
present study suggests that CYP genes play an important 
role in OS tumorigenesis, at primary and metastatic sites, 
as well in treatment response.
MATERIALS AND METHODS
Patients and specimens
We investigated 135 specimens from 37 patients 
with the diagnosis of OS admitted to treatment in 
the Pediatric Oncology Institute (IOP/GRAACC/
UNIFESP), between 2006 and 2011, with an average of 
16 years of age at diagnosis. Thus, the study included 
37 biopsies (pre-chemotherapy), 37 OS resected in 
surgery (post-chemotherapy), 37 nonmalignant bone 
tissues surrounding OS resected in surgery (adjacent 
bone - post-chemotherapy), 13 lung metastases and 11 
nonmalignant lung tissues surrounding OS metastases 
(adjacent lung). Lung metastasis and adjacent lung 
specimens were obtained from eight patients, in which 
four were metastatic patients at diagnosis. Four normal 
bone tissues were used as control, they were obtained 
from orthopedic surgeries of four healthy individuals 
that suffered a trauma and did not present either genetic 
disorders or bone diseases. Two different samples 
were used as control for the nonmalignant lung tissues 
surrounding metastases: one normal lung from a healthy 
individual without genetic disorders and one human lung 
total RNA from Thermo Fisher Scientific (Waltham, MA, 
USA). This study had the Research Ethics Committee 
approval from the Federal University of Sao Paulo (CEP 
UNIFESP 833694) and all patients agreed to participate by 
an informed consent. All patients were treated following 
the GLATO (Grupo Latino Americano de Tratamento de 
Osteossarcoma - Latin American Group of Osteosarcoma 
Treatment) protocol of 2006, which is based on high doses 
of cisplatin, doxorubicin and methotrexate. All clinical 
data are summarized in Table 1.
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Table 1: Clinical features of OS patients
Clinical features No. (%)
Metastasis at diagnosis
 Yes 6 (16)
 No 31 (84)
Location
 Femur 22 (59)
 Tibia 8 (22)
 Humerus 3 (8)
 Others 4 (11)
Size
 < 12 cm 26 (70)
 ≥ 12 cm 11 (30)
Histology
 Osteoblastic 18 (49)
 Condroblastic 4 (11)
 Fibroblastic 3 (8)
 Mixed 7 (19)
 Others 5 (13)
Grade of tumor necrosis
 < 90% 18 (49)
 ≥ 90% 17 (46)
 Not identified 2 (5)
Surgery
 Conservative 32 (87)
 Amputation 5 (13)
Relapse
 Yes 10 (27)
 No 27 (73)
Local of relapse
 Lung 7 (19)
 Bone 4 (11)
Metastasis
 Yes 11 (30)
 No 26 (70)
Local of metastasis
 Lung 10 (27)
 Bone 3 (8)
Status
 Alive 29 (78)
 Dead 8 (22)
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Cell lines
The human OS cell lines Saos-2, KHOS, MG-63, 
and U2-OS were purchased from the American Type 
Culture Collection (Rockville, MD, USA). The human 
cell line M-OS was established in our laboratory from a 
OS lung metastasis at diagnosis [44]. All cell lines were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS). All 
cells were cultured in a humidified incubator at 37°C and 
5% CO2.
Cytotoxicity assay and IC50
The half maximal inhibitory concentration (IC50) of 
each drug (cisplatin, doxorubicin and methotrexate) and 
their combinations were determined by the cytotoxicity 
assay. It was considered two combinations used during OS 
treatment: 1) cisplatin and doxorubicin (CD), combination 
used in the first chemotherapy of each cycle; 2) cisplatin, 
doxorubicin and methotrexate (CDM), considering 
together all drugs used in this treatment.
The cells were plated in a 96-wells plates with 100 
µl/well and 5x103 cells/well, except Saos-2 (1x104 cells/
well) and performed in triplicate for all cell lines. After 
overnight incubation to adhesion of cells, the medium was 
removed and drugs were added in serial concentrations 
(0.39–200 µg/ml). Untreated cells were used as control. 
After 24, 48, and 72h of incubation, the medium with 
drugs was removed and each well was washed with 200 
µl of phosphate-buffered saline (PBS). Then, 100 µl of 
PrestoBlue® Cell Viability Reagent (Invitrogen, Waltham, 
MA, USA) dissolved in DMEM was added in each well. 
After 2h of incubation, all plates were analyzed on the 
ELISA reader M3 Spectra Max (Molecular Devices, 
Sunnyvale, CA, USA). The IC50 values were calculated 
for every treatment and time.
qRT-PCR
All frozen tissues were submitted to RNA extraction 
using TRIzol® Reagent (Thermo Fisher Scientific, 
Waltham, MA, USA). All treated and untreated OS cell 
lines were submitted to RNA extraction using NucleoSpin 
Triprep® Kit (Macherey-Nagel, Duren, Germany). 
The cDNA was synthesized using SuperScript® 
Vilo™ Master Mix (Invitrogen, Waltham, MA, USA). 
The gene expression was measured by quantitative 
reverse transcription PCR (qRT-PCR) using SYBR® 
Green PCR Master Mix (Applied Biosystems™, 
Waltham, MA, USA). The ACTB and GAPDH genes 
were used as endogenous controls. Normal bone and 
normal lung were used as calibrators. All primers 
were designed using online tools (Clustal and NCBI 
primer express) and their sequences were: ACTB 
forward 5’-AAGGCCAACCGCGAGAAG-3’, reverse 
5’-ACAGCCTGGATAGCAACGTACA-3’; GAPDH 
forward 5’-ACAACTTTGGTATCGTGGAAGGA-3’, 
reverse 5’-TCTTCTGGGTGGCAGTGATG-3’; CYP1A2 
forward 5’-GCCTGAGATACAGAGGAAGATCCA-3’, 
reverse 5’-CGCTCCCTGCCAATCACA-3’; CYP3A4 
forward 5’-TATGCTCTTCACCGTGACCCAA-3’, reverse 
5’-CCTTGTTCTTCTTGCTGAAT-3’; and CYP3A5 
forward 5’-CCTCTGCCTTTGTTGGGAAATG-3’, 
reverse 5’- GCACTCTGTGTCAAATTTCCAGAG-3’. 
The relative quantification (RQ) was calculated by the 2−
ΔΔCt method.
Statistical analyses
Data analyses was performed using the GraphPad 
Prism version 6.0 for Windows (GraphPad Software, 
San Diego, CA, USA). IC50 values were calculated by 
the software. The gene expression, which is represented 
by the relative quantification, was compared using 
nonparametric tests: Wilcoxon, Mann-Whitney, 
Friedman, Kruskal-Wallis and Dunn’s multiple 
comparisons. The overall and event-free survivals were 
calculated by the Kaplan-Meier method and the survival 
curves were compared by the log-rank test. Statistical 
significance was taken when P<0.05.
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